Actively Recruiting
Phase 1 Randomized Study Comparing Pharmacokinetics of Two GSK5784283 Formulations in Healthy Adults by Injection
Led by GlaxoSmithKline · Updated on 2026-07-29
24
Participants Needed
1
Research Sites
1 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are comparing how two different forms of the study medicine GSK5784283 are processed in the bodies of healthy adults. This phase 1 study aims to understand the pharmacokinetics of GSK5784283, evaluating its safety, how well it is tolerated, and whether the two formulations behave similarly in the body. Participants will receive one of two versions of GSK5784283 by injection. The study is randomized and parallel in design, meaning participants are assigned to either the test or reference formulation without switching. The research includes monitoring blood levels of the drug over time to assess concentration and exposure. Participants will be involved in regular monitoring up to 253 days after dosing. This includes blood tests to measure drug levels, assessments for side effects or adverse events, laboratory tests, vital signs, and heart monitoring using ECGs. Researchers will also check for immune responses to the drug through antibody testing, ensuring comprehensive safety and effectiveness evaluations during the study period.
CONDITIONS
Brief Title
A Comparative Study to Investigate the Difference in Blood Levels of Two Different Formulations of GSK5784283
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
